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Traumatic spinal cord injury (SCI) causes irreparable severe motor and sensory dysfunction. Mechanical trauma
rapidly leads to blood-spinal cord barrier disruption, neural cell death, axonal damage, and demyelination, followed
by a cascade of secondary injury that expands the additional inflammatory reaction at the lesion site. Although the
role of inflammation in this phase is complex, a number of studies have suggested that inflammatory responses
spread the damage to the surrounding tissue, induce apoptotic cell death, and impair spontaneous regeneration
and functional recovery. However, recent advances in experimental technology, such as the depletion antibodies
for a specific fraction of inflammatory cells and the genetically engineered mice deficient only in specific cells,
suggest the beneficial aspects of inflammatory cells, such as a neuroprotective effect, the removal of cellular debris,
and the attenuation of the inflammatory reaction in general. In this review, I summarize our recent findings about
the biological role of inflammatory cells, especially infiltrating neutrophils and activated microglia after SCI. A better
understanding of the pathophysiological role of inflammation in the acute phase of SCI will aid in the development
of therapeutic strategy to enhance the functional recovery after SCI.
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Traumatic spinal cord injury (SCI) is a major public
health problem and a devastating event for individuals
that causes permanent severe motor/sensory dysfunction
and significantly degrades the quality of life. SCI is
known to result in neurological deficits through both
the primary and secondary damage. The “primary” injury
encompasses the immediate mechanical damage to the
spinal cord tissue that occurs at the moment of impact,
which is irreversible and not preventable. The “secondary”
injury, by contrast, is incurred as a result of the patho-
logical processes initiated at the time of the primary injuryCorrespondence: seokada@ortho.med.kyushu-u.ac.jp
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Inflammatory reaction and the secondary injury
In the secondary injury process of SCI, the infiltration of
leukocytes and activation of glial cells can aggravate tissue
damage by releasing proteases, reactive oxygen intermedi-
ates, lysosomal enzymes, and proinflammatory cytokines/
chemokines [1, 2]. Although the role of inflammation in
this phase is complex, with certain beneficial aspects as
well, such as the removal of cellular debris, a number of
studies have suggested that inflammatory responses
spread the damage to surrounding tissue, induce apoptotic
cell death, and impair spontaneous regeneration and
functional recovery [3]. To protect the injured spinal cord
from these secondary pathological processes, severalle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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have been assessed and found effective. These approaches
include the blockage or neutralization of specific cytokine
signaling using a monoclonal antibody, the delivery of
anti-inflammatory drugs, and the use of genetically modi-
fied animals. Indeed, we previously examined whether or
not the administration of IL-6 receptor antibody immedi-
ately after SCI attenuated the secondary injury and caused
a therapeutic effect, since IL-6 is a principal proinflamma-
tory cytokine in SCI [4].
IL-6 signaling plays roles in regulating various steps in
inflammatory reactions, such as the activation and infil-
tration of neutrophils, monocytes, macrophages, and
lymphocytes. Indeed, previous studies from other research
groups have reported that the delivery of the IL-6/sIL-6R
fusion protein to spinal cord injury sites induced a sixfold
increase in neutrophils and a twofold increase in macro-
phages and microglial cells and expanded the damaged
area [5]. We therefore speculated that blockage of IL-6
signaling would suppress the inflammatory response and
ameliorate the secondary injury after SCI. We found that
the number of infiltrated macrophages as well as scar tis-
sue formation was significantly reduced, resulting in
improved functional recovery [4]. The same strategy con-
ducted later by other groups also demonstrated that the
temporary inhibition of IL-6 signaling reduced the infiltra-
tion of hematogenous macrophages and the activation of
the phagocytic activity of microglial cells [6, 7]. In addition
to the anti-inflammatory effect, this approach also had a
number of additional effects, including the attenuation of
glial scar formation and preservation of neuroprotective
phosphatidylcholine [8]. Moreover, a clinical merit of this
strategy is that humanized antibody to human IL-6R
(ACTEMRA®, tocilizumab) has already been in wide-
spread use for rheumatoid arthritis and its efficacy as well
as safety profile was confirmed.
However, in contrast to these reports, IL-6 itself was
reported to enhance spinal cord repair by modifying the
migration of reactive astrocytes or enhancing axonal re-
growth [9, 10]. Although these results seem inconsistent,
this contributes to the consequence of the context-
dependent pleiotropic actions of IL-6 in SCI. During the
acute phase of SCI, IL-6 family cytokines act primarily
as potent proinflammatory mediators and cause secondary
injury but also enhance the repair process after the sub-
acute phase of SCI. These findings for IL-6 signaling
suggest that the inflammatory response in SCI is very com-
plicated and has context-dependent pleiotropic actions.
Flow cytometric evaluation of infiltrating leukocytes in SCI
In the research field of SCI, the conventional evaluation
of inflammatory cell infiltration has been mainly limited
to histological analyses. However, accurate quantification
with histology is relatively difficult, as the lesion site istoo fragile to treat in the acute phase of injury when the
most prominent cell infiltration is observed. We there-
fore have induced flow cytometry, which enables the ac-
curate detection and direct isolation of these cells for
the evaluation of inflammatory cells after SCI [11]. With
this method, we were able to quantitatively examine the
detailed profile of infiltrated leukocytes into the lesion
area (Fig. 1). The infiltrated neutrophil population had
increased dramatically 12 h after SCI and remained at a
high level for up to 1 day before gradually decreasing
thereafter. Although the peak monocyte/macrophage in-
filtration is commonly understood to occur at a later
phase than neutrophil infiltration, including in human
SCI [12–14], we found that that monocyte/macrophage
infiltration also peaked at 12 h after SCI. In addition, the
temporal change in the number of infiltrated mono-
cytes/macrophages was completely different from that of
the microglial cells, which dramatically increased at
7 days after SCI. We attribute this discrepancy between
the present and previous reports to the shortcomings of
the immunohistological analyses, which have difficulty in
discriminating infiltrated monocytes/macrophages from
resident microglial cells. This methodology enables us to
quantify not only the accurate number of the cells at
multiple time points after SCI but also the secretory ac-
tivity of the inflammatory mediators by sorting the in-
flammatory cell fractions [11].
Modulation of infiltrating neutrophils after SCI
Among the infiltrating leukocytes in the acute phase of
SCI, neutrophils are considered to be one of the most
potent triggers of post-traumatic spinal cord damage,
which occurs through the release of proteases, reactive
oxygen intermediates, nitric oxide, and lysosomal en-
zymes. Despite the fact that neutrophils are essential for
innate immunity and important as anti-infectious factors
in host defense, several studies focusing on the suppres-
sion of neutrophil infiltration have reported reduced se-
verity of secondary injury and better functional recovery
after SCI [15, 16].
The process of neutrophil infiltration to the lesion site
is enhanced and amplified by variety of factors, such as
proinflammatory cytokines, eiconosides, and adhesion
molecules. Of these factors, leukotriene B4 (LTB4) is a
highly potent lipid chemoattractant for neutrophils.
LTB4 is produced rapidly by arachidonic acid cascade
from membrane phospholipids without any requirement
of transcription or translation and is mediated by its
high-affinity specific receptor LTB4 receptor 1 (BLT1)
[17]. In addition to this effect, LTB4 activates neutro-
phils that promote lysosomal enzyme release and super-
oxide production. This LTB4 biosynthesis system exerts
its effect on the injured tissue faster than other inflam-
matory cytokines and chemokines, implying that LTB4
Fig. 1 Time course of infiltrating inflammatory cells in injured spinal cord. A quantitative time course evaluation of the infiltrated neutrophils
(CD45+CD11b+Gr-1+ fraction), macrophages (CD11b+Gr-1−CD45high), and microglial cells (CD11b+Gr-1−CD45int) in the SCI mice (Th9 contusion
injury, 70 kdyn). Dot plots and graph data (n = 6 in each time point) were quoted from [13]
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cascade [18].
Previous studies have demonstrated that LTB4 is not
only an important mediator in the regulation of micro-
bial infection but also deeply related to several inflamma-
tory diseases, autoimmune diseases, and atherosclerosis
[19–22]. However, as for traumatic injury, the physio-
logical role of LTB4 is not yet well understood. In
addition, few analyses have examined the relationship be-
tween LTB4 and pathophysiology after SCI, although
LTB4 may be a major contributive factor for inflammatory
cell infiltration.
We therefore analyzed the pathophysiological involve-
ment of LTB4 in a mouse SCI model using BLT1-
deficient mice. Our results showed that BLT1-knockout
mice exhibited a 23 % decrease in neutrophils and 10 %
decrease in macrophages after SCI compared to the
wild-type mice [11]. These reduced numbers of infil-
trated leukocytes resulted in the suppression of neural
apoptosis, less demyelination, and reduced proinflamma-
tory cytokine expression as well as better functional re-
covery in BLT1-knockout mice than in wild-type mice
[11]. These results showed that the LTB4-BLT1 pathway
was indeed involved in the pathogenesis of traumatic
secondary damage through the amplification of neutrophils
and macrophages infiltration, suggesting that neutralizingLTB4 has potential as a therapeutic strategy during the
acute phase of SCI.
Pathophysiological role of microglia in SCI
Microglial cells constitute about 10 % of the adult cen-
tral nervous system (CNS) cell population and represent
the innate immune system of the spinal cord. Under
pathological conditions such as neurodegenerative dis-
ease, stroke, tumor invasion, and traumatic injury, these
cells become activated, surround damaged and dead
cells, and clear cellular debris from the area, much like
the phagocytic macrophages of the immune system [23].
In healthy mammalian brain tissue, microglia display
characteristically elongated cell bodies with spine-like
processes that often branch perpendicularly. Although
microglia were initially believed to be essentially quies-
cent cells, recent studies have revealed that they are con-
tinually surveying their microenvironment and represent
the first line of defense against invading pathogens or
other types of CNS tissue injury [24, 25]. Indeed, we
found that the spinal microglial secretory activity was
quickly stimulated at 3 h post SCI in response to patho-
logical changes, while the infiltration of other leukocytes
peaked at 12 h post SCI [11, 26]. In addition, we demon-
strated that microglial activity was significantly attenu-
ated in young mice compared to adult mice, with
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as better functional recovery in the younger mice than
in the older ones [26]. The expressions of potent chemo-
attractant for neutrophil infiltration, IL-6, and CXCL1
were also significantly reduced in the microglia isolated
from the young mice. Considering that these chemoat-
tractants are dominantly secreted by activated microglia
and that microglial activation occurred prior to the infil-
tration of leukocytes, microglial activity appears to be
critical for the trigger of propagation and enhancement
of the inflammatory response. Leukocytes that infiltrate
the lesion site also produce cytokines/chemokines by
interaction with the other immune cells or microglial
cells, leading to the amplification of the chemotactic gra-
dient and to further infiltration of leukocytes to the le-
sion site [27]. We therefore believe that the reduced
immediate activation of microglial cells in young mice
results in the decreased infiltration of neutrophils, lead-
ing to reduced amplification/exaggeration of the inflam-
matory response in SCI.
Although the precise mechanisms of microglial activa-
tion remains unclear, several basic research studies have
reported that hyperglycemia is involved in the activation of
resident monocytic cells, including microglia. For example,
the number of pancreatic resident monocytes is increased
in hyperglycemic rodents, leading to the up-regulation of
islet-derived inflammatory factors, such as IL-6 and IL-8
[28]. In addition, peritoneal monocytes are activated under
hyperglycemic conditions, subsequently inducing a greater
production of TNFα than that associated with a normo-
glycemic state [29]. Furthermore, hyperglycemia correlates
with worsening of tactile allodynia accompanied by the
hyperactivation of dorsal horn microglia [30].Fig. 2 Hyperglycemia in the acute phase of SCI is associated with poor funBecause microglial activation is associated with sec-
ondary injury after SCI, we hypothesized that hypergly-
cemia may also influence the pathophysiology of SCI by
altering microglial responses. We thus investigated the
effects of hyperglycemia on the pathophysiological pro-
cesses and motor functional outcomes in two experi-
mental mouse models of hyperglycemia in the acute
phase of injury [31]. An in vivo cell type-specific gene
expression analysis with flow cytometry revealed en-
hanced the proinflammatory reactivity in the microglial
cells of the hyperglycemic mice. We found that hyper-
glycemia induced the overactivation of NF-kB in micro-
glial cells as well as excessive inflammation, resulting in
a poor functional recovery after SCI [31]. We also con-
ducted a multivariable linear regression analysis of the
clinical data obtained from 528 human SCI subjects,
which provided entirely new evidence showing that
acute phase hyperglycemia is a critical factor in the poor
functional outcomes of SCI. Finally, we showed that
achieving glycemic control can ameliorate the patho-
logical and functional outcomes of hyperglycemic mice,
thus supporting the existence of a direct relationship be-
tween acute hyperglycemia and the exacerbation of SCI
outcomes [31] (Fig. 2).
With regard to the mechanisms involved in the
hyperglycemia-related overactivation of NF-kB in micro-
glia, NADPH oxidase is considered to possibly play a
role. NADPH oxidase is present in several types of
phagocytes, including microglia, causing inflammatory
activation of these cells [32]. In addition, several studies
have reported that hyperglycemia enhances the NADPH
oxidase activity in innate immune cells [33, 34]. Further-
more, NADPH oxidase is known to produce reactivectional outcomes
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translocation of NF-kB [36]. Therefore, hyperglycemia
may promote the translocation of NF-kB in microglial
cells via the NADPH oxidase/ROS/NF-kB pathway. The
fact that the increased expression of NADPH oxidase
and ROS has been confirmed in spinal microglial cells
after injury also supports the role of this pathway [37].
These findings shed light on the importance of achieving
tight glycemic control in acute human SCI to obtain bet-
ter neurological outcomes, also providing a better under-
standing of the inflammatory machinery after SCI.
Resolution of acute inflammation after SCI
Although the acute inflammation after SCI spontan-
eously diminishes within a short period of time, the
mechanism underlying this inflammatory resolution is
largely unknown. Recently, we demonstrated that the
infiltrating Ly6C+Ly6G− immature monocyte fraction
exhibited the same characteristics as myeloid-derivedFig. 3 Three subsets of CD45+CD11b+ infiltrating cells and their each phen
harvested at 4 days after injury and subjected to a flow cytometric analysis
quantitative RT-PCR. *p < 0.05 using a Kruskal–Wallis H test, with Bonferronisuppressor cells (MDSCs) and played a critical role in
the resolution of acute inflammation and in the subse-
quent tissue repair after SCI [38].
Immediately after SCI, a large number of CD11b+Gr-1+
inflammatory cells infiltrated the lesion area and led to the
secondary damage of neural tissue. Although Gr-1 surface
antigen is a common epitope on Ly6C and Ly6G, which
express monocytic and granulocytic subsets, respectively,
the detailed role of each subset at the lesion areas remains
elusive. We therefore evaluated the temporal change in
the infiltration of Ly6C+Ly6G−, Ly6C−Ly6G−, and Ly6C−
Ly6G+ cell subsets in the CD45+CD11b+ fraction by flow
cytometry from 4 h until 7 days after SCI [38]. The flow
cytometry analysis revealed that the infiltrating Ly6C−
Ly6G+ and Ly6C+Ly6G− fractions had similar patterns of
change, peaking at 12 h after injury, whereas the Ly6C−
Ly6G− fraction increased gradually with time. To investi-
gate the physiological roles of these myeloid-derived
inflammatory cell subsets after SCI, we used FACS tootype. Injured mice spinal cords (Th9 contusion injury, 70 kdyn) were
. Ly6C+Ly6G−, Ly6C−Ly6G+, and Ly6C−Ly6G− fractions were analyzed by
’s post hoc correction. Data were quoted from [38]
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Ly6G cell surface antigens. We confirmed that the flow
cytometry-sorted Ly6C-Ly6G+ fraction expressed signifi-
cantly higher levels of CXCR1 and CXCR2, the Ly6C+
Ly6G− fraction expressed a higher level of CCR2, and the
Ly6C−Ly6G− fraction expressed higher levels of CX3CR1
than the other fractions, which indicated that each subset
was regulated by different chemokines. The infiltrating
Ly6C−Ly6G+ fraction showed proinflammatory properties
with elevated expression of IL-1β and TNFα. In contrast,
we confirmed that the Ly6C+Ly6G− fraction had elevated
expression of both iNOS and arginase 1 (Fig. 3). This ex-
pression pattern is a typical feature of MDSCs, which
exert immunosuppressive effects by modulating macro-
phage activation toward an immunosuppressive pheno-
type. In addition, the Ly6C+Ly6G− fraction had elevated
expression of anti-inflammatory mediators such as IL-10,
TGFβ, and VEGF, which is also consistent with the typical
features of MDSCs. We also demonstrated that complete
depletion of this population resulted in prolonged inflam-
mation and significantly exacerbated tissue edema, vessel
permeability, and hemorrhaging, causing impaired neuro-
logical outcomes. Furthermore, the transplantation of
MDSCs at lesion areas significantly attenuated acute in-
flammation and promoted tissue repair, which improved
neurological outcomes after SCI [38].
Among the anti-inflammatory factors from Ly6C+
MDSCs, IL-10 functions as a potent inducer of HO-1 in
macrophages [39]. HO-1 is a heme-degrading enzyme
that protects tissues from free heme toxicity. In addition,
it also has a direct effect of attenuating inflammation
[40]. We confirmed that transplantation of MDSCs sig-
nificantly up-regulated HO-1 expression, suggesting that
MDSCs created an environment favorable for tissue re-
pair. In addition, the expression of both arginase 1 and
iNOS was enhanced in the lesion areas after MDSC trans-
plantation for 1 week after SCI [38]. This up-regulation of
both arginase 1 and iNOS was a determining factor for de-
fining the characteristics of MDSCs. These findings clari-
fied the role of MDSCs after traumatic SCI and suggested
the potential utility of an MDSC-based therapeutic strat-
egy for the acute phase of SCI.
Conclusions
Although inflammatory reactions lead to further damage
and dysfunction after SCI, we confirmed that complete
neutrophil depletion using the Gr-1 antibody severely
impaired the functional recovery in a mouse SCI model.
Thus, whether or not neuroinflammation after SCI has a
neurotoxic or neuroprotective effect remains highly con-
troversial. Although only minor attention has been paid
to the role of inflammation in tissue protection after SCI
thus far, it could be an essential factor for a well-balanced
inflammatory reaction under pathological conditions.Nevertheless, more basic research should be conducted to
clarify the detailed pathophysiological role of inflamma-
tion after SCI, which suggest a new approach for SCI
treatment by modifying the inflammatory response in SCI.
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